Clearly tavr is the selling point now. The valuations page is interesting and shows this clearly, with tavr many multiples of adapt. $5.6m for infusion as the base valuation means it's unlikely the proposed sale will be much of an answer to financial issues, but getting rid of it will help with getting more r&d grants / rebates.
- Forums
- ASX - By Stock
- AVR
- New analyst report from NDF Research
New analyst report from NDF Research, page-4
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$12.90 |
Change
0.000(0.00%) |
Mkt cap ! $272.6M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 470 | $12.71 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.99 | 719 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2000 | 12.700 |
2 | 1100 | 12.500 |
1 | 60 | 12.250 |
1 | 85 | 11.620 |
1 | 1500 | 11.610 |
Price($) | Vol. | No. |
---|---|---|
12.990 | 719 | 2 |
13.000 | 250 | 1 |
13.200 | 250 | 1 |
13.250 | 100 | 1 |
13.440 | 246 | 1 |
Last trade - 10.05am 18/09/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
Day chart unavailable